Disruptions in Renal Stone Management during the COVID-19 Pandemic: a Retrospective Single-Center Study.

Objectives: This study evaluated changes in renal stone management during the COVID-19 pandemic in a single center, focusing on treatment methods, patient outcomes and healthcare delivery models.

Materials And Methods: We conducted a retrospective analysis comparing patients treated for kidney stones between July-September 2019 (pre-pandemic period) and July-September 2020 (pandemic period). We assessed the number of treated patients, treatment modalities and postoperative outcomes.

The Experience of SARS-CoV-2 in Patients with Benign Prostatic Hyperplasia: Is There Any Correlation between Them?

Recent studies suggest that the international prostate symptom score (IPSS), especially in older men, may result from COVID-19, and that LUTS may be high in the early stages of the illness. The primary goal of the present review is to ascertain the true impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the development of patients with benign prostatic hyperplasia (BPH) by analyzing the body of available literature. By May 2023, a comprehensive and categorized search of the literature was conducted utilizing the following global databases: the Cochrane Library, Web of Science, PubMed, Embase and Scopus.

Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic regulators of glioma growth.

Diffuse infiltrating gliomas are aggressive tumors of the central nervous system driven by intra-tumoral heterogeneity and aberrant normal-tumor cell-cell interactions. Grade specific and locoregional metabolic dependencies driving aberrant cell-states linked to treatment resistance, seizures and infiltration of gliomas remain elusive. Here, we applied spatial transcriptomics (stRNAseq), imaging mass cytometry (IMC) and mass spectrometry imaging (MSI; metabolites, peptides and glycans) to the core and edge tumor tissue from patients with World Health Organization (WHO) grades 2-4 diffuse infiltrating gliomas including isocitrate dehydrogenase (IDH) mutant oligodendrogliomas (WHO Grades 2 and 3) and IDH wildtype astrocytomas including 'anaplastic' astrocytoma (prior 2016 WHO histological grade 3) and glioblastoma (GBM, WHO grade 4) stRNAseq identified regions-specific differentially expressed genes with significant overall survival implications particularly in IDH wildtype GBM.